November 16, 2010
The American Lawyer
After nearly four years of litigation and a three-week bench trial in August, Bristol-Myers and its partner Otsuka Pharmaceutical Co. finally convinced a federal district court judge in New Jersey to block Apotex, Novartis, Sun, and Teva from selling generic versions of the antipsychotic Abilify®, which generated nearly $2 billion in sales in the first nine months of 2010. Otsuka, which developed Abilify® and markets the drug in partnership with Bristol-Myers, sued the generics for patent infringement in early 2007, after they or their predecessor companies filed applications with the U.S. Food & Drug Administration to sell generic versions of Abilify® in the United States. The ruling states that generics will not be able sell their versions of Abilify® in the U.S. until an Otsuka patent on the drug expires in 2015.
Media Mention
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.